ProMIS Neurosciences to Present at Notable Conference
CAMBRIDGE, Massachusetts — ProMIS Neurosciences, Inc. (NASDAQ: PMN), a cutting-edge biotechnology firm, is dedicated to developing antibody therapeutics that target toxic misfolded proteins in conditions such as Alzheimer's disease and ALS. The company has announced an exciting opportunity for insights and discussion as Neil Warma, the CEO, is set to participate in a fireside chat at the prominent Roth Conference.
Fireside Chat Details
Scheduled for Tuesday, attendees can expect valuable discussions beginning at 8:00 a.m. PT in Dana Point, where Warma will highlight the innovative research and development strategies at ProMIS Neurosciences. This chat will delve into the company’s mission to advance therapeutic options for neurodegenerative diseases, emphasizing the importance of targeted treatment approaches.
Accessing the Webcast
A live webcast of the fireside chat will be available, making it accessible to a broader audience. Interested participants can visit the company’s website to join the session and gain insights that will be retained for at least 30 days post-event.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences has a strong commitment to improving the lives of individuals afflicted with neurodegenerative conditions. Utilizing their advanced discovery platform, known as ProMIS™, the company has pioneered methods to identify Disease Specific Epitopes that present novel therapeutic targets.
Leading the Charge with PMN310
The flagship product, PMN310, is a humanized monoclonal antibody developed specifically to bind to toxic A? oligomers — a critical factor in Alzheimer’s disease progression. Unlike traditional antibodies, PMN310 is designed to avoid binding to plaque or monomers, showcasing its innovative specificity. This product has already successfully completed Phase 1a trials and is currently being administered in Phase 1b clinical trials.
Corporate Commitment and Future Directions
ProMIS Neurosciences operates out of two locations in Cambridge, Massachusetts, and Toronto, Ontario, signaling its dual commitment to innovation and collaboration across borders. As neurodegenerative diseases continue to challenge healthcare systems, ProMIS is dedicated to delivering effective treatments.
Staying Informed
Those interested in the latest advances in neurology can find extensive information on the ProMIS Neurosciences website. Additionally, for media inquiries, interested parties are encouraged to reach out via provided contact information.
Frequently Asked Questions
What is ProMIS Neurosciences known for?
ProMIS Neurosciences specializes in developing antibody therapeutics targeting toxic misfolded proteins associated with neurodegenerative diseases.
When is the Roth Conference taking place?
The Roth Conference fireside chat featuring ProMIS Neurosciences is set for Tuesday, at 8:00 a.m. PT.
How can I access the webcast of the chat?
The live webcast can be accessed through the company's website, with availability for at least 30 days following the event.
What is PMN310?
PMN310 is ProMIS's lead product candidate, designed to bind selectively to toxic A? oligomers and is currently undergoing clinical trials for Alzheimer’s disease.
Where are the company’s offices located?
ProMIS Neurosciences operates in Cambridge, Massachusetts, and Toronto, Ontario.
